Abstract
In the indication of allergic rhinoconjunctivitis, allergen immunotherapy (AIT) is currently administered subcutaneously or sublingually and is suitable for children from the age of five, as well as for adolescents and adults with pollen binding, pets, house dust mites. It not only affects the symptoms of rhinoconjunctivitis, but also has short-term and long-term effects to reduce the development of asthma.
In the indication of allergic asthma, AIT has demonstrated a preventive effect in reducing the development of allergic inflammation, according to the international document and asthma treatment (GINA 2016), sublingual AIT is included in the basic treatment modalities of bronchial asthma with mite-related , more than 70% of the appropriate value. Immunomodulation of allergic disease by AIT leads to a reduction in the severity of the disease, a reduction in the use of pharmacotherapy, has an effect in reducing subsequent sensitization and a long-term preventive effect.